Royal Bank of Canada
EBACU

Royal Bank of Canada’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Royal Bank of Canada’s Portfolio EBACU Stock Details EBACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-41,390
Closed -$408K – 8036
2022
Q1 		$408K Hold
41,390
– – ﹤0.01% 4432
2021
Q4 		$410K Sell
41,390
-175
-0.4% -$1.73K ﹤0.01% 4656
2021
Q3 		$413K Buy
41,565
+148
+0.4% +$1.47K ﹤0.01% 4517
2021
Q2 		$413K Sell
41,417
-1,425
-3% -$14.3K ﹤0.01% 4452
2021
Q1 		$432K Buy
+42,842
New +$428K ﹤0.01% 4314

Other funds holding EBACU

FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SMA
Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.34% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.72% 1-Year Est. Return

Royal Bank of Canada's EBACU Position: Q2 2022 in Review

Royal Bank of Canada sold out of European Biotech Acquisition Corp. Units (EBACU) in Q2 2022, closing a stake of 41,390 shares — an estimated $408K sold.

Royal Bank of Canada first reported a position in EBACU in Q1 2021 and held it in 5 quarters. The position peaked at $432K in Q1 2021. 20 funds tracked by Wall St. Rank hold EBACU as of Q2 2022.

  • Royal Bank of Canada reported no remaining European Biotech Acquisition Corp. Units position as of Q2 2022 after selling out during the quarter.
  • Royal Bank of Canada sold 41,390 European Biotech Acquisition Corp. Units shares in Q2 2022, an estimated $408K.
  • Royal Bank of Canada first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 5 quarters.
  • Royal Bank of Canada's European Biotech Acquisition Corp. Units position peaked at $432K in Q1 2021.
  • 20 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q2 2022.

Based on Royal Bank of Canada's 13F filing for Q2 2022, filed 15 Aug 2022.